4 1 a34564.txt FRED HASSAN Form 4 Page 1 of 2 ---------------------------- --------------- OMB APPROVAL FORM 4 ---------------------------- --------------- OMB Number: 3235-0287 ---------------------------- Expires: January 31, 2005 ---------------------------- Estimated average burden hours per response... 0.5 ---------------------------- [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). (Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

------------------------------------------------------------------------------------------------------------------------ 1. Name and Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol Hassan, Fred Pharmacia Corporation PHA ------------------------------------------------------------------------------------------------------------------------ (Last) (First) (Middle) 3. I.R.S. Identification 4. Statement for Number of Reporting Month/Day/Year Person, if an entity 04/16/2003 (voluntary) 100 Route 206 North ------------------------------------------------------------------------------------------------------------------------ (Street) 5. If Amendment, Date of Original (Month/Day/Year) Peapack, NJ 07977 ------------------------------------------------------------------------------------------------------------------------ (City) (State) (Zip)

Form 4 Page 2 of 2 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) -------------------------------------------------------------------------------------------------------------------- 1. Title of Derivative 2. Conver- 3. Trans- 3A. Deemed Execution 4. Transac- 5. Number of Security (Instr. 3) sion or action Date, if any tion Code Derivative Exercise Date (Month/Day/Year) (Instr. 8) Securities Price of (Month/ Acquired (A) Derivative Day/ or Disposed of Security Year) (D) (Instr. 3, 4 and 5) ----------------------------------- Code V (A) (D) -------------------------------------------------------------------------------------------------------------------- Option (right to buy) $25.47 04/16/2003 J(1) 627,970 -------------------------------------------------------------------------------------------------------------------- Option (right to buy) $31.87 04/16/2003 J(1) 376,782 -------------------------------------------------------------------------------------------------------------------- Option (right to buy) $43.49 04/16/2003 J(1) 502,376 -------------------------------------------------------------------------------------------------------------------- Option (right to buy) $35.35 04/16/2003 J(1) 188,391 -------------------------------------------------------------------------------------------------------------------- Option (right to buy) $39.06 04/16/2003 J(1) 439,579 -------------------------------------------------------------------------------------------------------------------- Option (right to buy) $48.88 04/16/2003 J(1) 527,706 -------------------------------------------------------------------------------------------------------------------- Option (right to buy) $46.52 04/16/2003 J(1) 633,247 -------------------------------------------------------------------------------------------------------------------- Option (right to buy) $39.27 04/16/2003 J(1) 1,052,866 -------------------------------------------------------------------------------------------------------------------- Option (right to buy) $39.27 04/16/2003 J(1) 2,546 -------------------------------------------------------------------------------------------------------------------- Performance Share Units 1-for-1 04/16/2003 J(1) 326,623 -------------------------------------------------------------------------------------------------------------------- Performance Stock Units 1-for-1 04/16/2003 J(1) 134,766 --------------------------------------------------------------------------------------------------------------------

Explanation of Responses: (1) Each share of Pharmacia Common Stock (PHA) held by the reporting person was exchanged for 1.4 shares of Pfizer Common Stock (PFE), pursuant to the Pfizer/Pharmacia merger agreement adopted by the Pfizer and Pharmacia shareholders on December 6 & 9, 2002, respectively. (2) Option is currently exercisable. (3) Target awards provided under the Founders Performance Contingent Shares Program vest at the greater of the target award or the percentage of the target award payable based on the period-to-date performance calculated as of the date of the change in control. The award increases to 125% of the participant's target award if the participant is employed by the company or an affiliate two years after the change in control, or is involuntarily terminated other than for cause within two years after change in control and, is such amount is greater than the calculation above. (4) At the end of each calendar year 2002, 2003 and 2004, 1/3 of the units will be eligible for allocation based on Company performance for that year. (5) Distribution under the plan commences the calendar year following retirement, termination, death or disability, based on the provisions of the Savings+Plus deferred compensation plan. /s/ Don W. Schmitz April 16, 2003 -------------------------------- ----------------- **Signature of Reporting Person Date Don W. Schmitz, attorney-in-fact for Fred Hassan Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. *If the form is filed by more than one reporting person, see Instruction 4(b)(v). **Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

PHARMACIA CORP /DE/ 4